TUYADO

Serial Number 90711374
734

Registration Progress

Application Filed
May 14, 2021
Under Examination
Jul 28, 2022
Approved for Publication
Feb 1, 2022
Published for Opposition
Feb 1, 2022
Registered

Attorney Assistance

Statement of Use Due - Extension 5 Granted
Due: Nov 29, 2025 120 days
Statement of Use required (all extensions used)

Trademark Image

TUYADO

Basic Information

Serial Number
90711374
Filing Date
May 14, 2021
Published for Opposition
February 1, 2022
Drawing Code
4

Status Summary

Current Status
Active
Status Code
734
Status Date
Apr 23, 2025
Application
Pending
Classes
005

Rights Holder

JOHNSON & JOHNSON

03
Address
One Johnson & Johnson Plaza
New Brunswick, NJ 08933

Ownership History

JOHNSON & JOHNSON

Original Applicant
03
New Brunswick, NJ

JOHNSON & JOHNSON

Owner at Publication
03
New Brunswick, NJ

Legal Representation

Attorney
Danielle R. Weitzman

USPTO Deadlines

Next Deadline
120 days remaining
Statement of Use Due - Extension 5 Granted
Due Date
November 29, 2025

Application History

40 events
Date Code Type Description Documents
Apr 23, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Apr 23, 2025 EX5G S SOU EXTENSION 5 GRANTED Loading...
Apr 22, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 22, 2025 EXT5 S SOU EXTENSION 5 FILED Loading...
Jan 25, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 24, 2025 EX4G S SOU EXTENSION 4 GRANTED Loading...
Jan 22, 2025 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Nov 15, 2024 EXT4 S SOU EXTENSION 4 FILED Loading...
Nov 15, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 18, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Apr 17, 2024 EX3G S SOU EXTENSION 3 GRANTED Loading...
Apr 17, 2024 EXT3 S SOU EXTENSION 3 FILED Loading...
Apr 17, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 13, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 11, 2023 EX2G S SOU EXTENSION 2 GRANTED Loading...
Oct 11, 2023 EXT2 S SOU EXTENSION 2 FILED Loading...
Oct 11, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Dec 21, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Dec 19, 2022 EX1G S SOU EXTENSION 1 GRANTED Loading...
Dec 19, 2022 EXT1 S SOU EXTENSION 1 FILED Loading...
Dec 19, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 29, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Oct 17, 2022 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Oct 17, 2022 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Oct 17, 2022 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Oct 17, 2022 NEWN I NEW NOA TO ISSUE Loading...
Jul 28, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jul 26, 2022 IUCN S NOTICE OF ALLOWANCE CANCELLED Loading...
Jun 12, 2022 ETOP T EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED Loading...
Mar 3, 2022 ETOF T EXTENSION OF TIME TO OPPOSE RECEIVED Loading...
Feb 1, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 1, 2022 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 12, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Dec 28, 2021 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 23, 2021 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 24, 2021 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Nov 24, 2021 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Nov 24, 2021 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Aug 12, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
May 18, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, digital ulcers, and cerebrovascular diseases; vaccines; anxiolytics; anti-allergics; anti-infectives

Classification

International Classes
005